Neurocrine Biosciences

Yahoo Finance • 11 days ago

Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally

Key Points New York City-based Armistice Capital sold 2,152,000 shares of Travere Therapeutics for an estimated $29.3 million in the third quarter. At quarter-end, the fund reporting holding 6.7 million shares of Travere Therapeutics valu... Full story

Yahoo Finance • 29 days ago

Alnylam Stock Has Almost Doubled In 2025. But It Took A Hit On Earnings.

Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Goldman says these 20 overlooked stocks are poised to spike this coming earnings season

Goldman Sachs has homed in on a list of stocks to pay attention to this earnings season. The bank highlighted 20 stocks it believes could spike on Q3 results. "Buy calls to position for a volatile but positive earnings season," derivatives... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

Health care stocks declined late Monday afternoon, with the NYSE Health Care Index easing 0.3% and t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 2 months ago

Nanobiotix gains after early-stage trial data for J&J-partnered cancer drug

[Cancer cells vis] koto_feja Nanobiotix (NASDAQ:NBTX [https://seekingalpha.com/symbol/NBIX]) traded higher on Thursday after the French biotech announced initial results from a Phase 1 trial for JNJ-1900 (NBTXR3), a cancer injection devel... Full story

Yahoo Finance • 2 months ago

Should You be Optimistic on Neurocrine Biosciences (NBIX)?

PGIM, an investment management company, released its “PGIM Jennison Health Sciences Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Equities in the second quarter of 2025 experienced significant vola... Full story

Yahoo Finance • 3 months ago

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Prime GARP Candidate with Strong Growth and Reasonable Valuation

Investors seeking growth opportunities without overpaying often turn to the Growth At Reasonable Price (GARP) strategy, which targets companies demonstrating strong expansion metrics alongside reasonable valuations. This approach avoids bo... Full story

Yahoo Finance • 3 months ago

Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access

We recently compiled a list of the 11 Best Pharma Stocks to Invest in for the Long Term. Neurocrine Biosciences, Inc. is one of them. Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a biopharmaceutical company focused on neurological, neuroen... Full story

Yahoo Finance • 4 months ago

Guggenheim raises Neurocrine Bio. stock price target on strong Ingrezza sales

Investing.com - Guggenheim raised its price target on Neurocrine Biosciences (NASDAQ:NBIX) to $175.00 from $165.00 on Thursday, while maintaining a Buy rating following the company’s second-quarter earnings report. The $13.15 billion marke... Full story

Yahoo Finance • 4 months ago

Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Pick with Solid Fundamentals

Investors looking for growth opportunities at fair prices often consider strategies such as Growth At a Reasonable Price (GARP) or "Affordable Growth." This method focuses on finding companies with strong growth potential while steering cl... Full story

Yahoo Finance • 4 months ago

Neurocrine refines INGREZZA net sales guidance to $2.5B-$2.55B while CRENESSITY surges, driving revenue growth and pipeline expansion

Earnings Call Insights: Neurocrine Biosciences (NBIX) Q2 2025 MANAGEMENT VIEW * CEO Kyle W. Gano highlighted "standout second quarter that delivered high double-digit growth which showcased our diversified revenue profile and highlight... Full story

Yahoo Finance • 4 months ago

Neurocrine Biosciences Inc Q2 Profit Increases, Beats Estimates

(RTTNews) - Neurocrine Biosciences Inc (NBIX) announced a profit for its second quarter that Increased from the same period last year and beat the Street estimates. The company's bottom line came in at $107.5 million, or $1.06 per share.... Full story

Yahoo Finance • 4 months ago

Neurocrine Biosciences Inc (NASDAQ:NBIX) Beats Q2 2025 Earnings Estimates but Stock Drops 8.6% on Investor Concerns

Neurocrine Biosciences Inc (NASDAQ:NBIX [https://www.chartmill.com/stock/quote/NBIX]) reported its second-quarter 2025 financial results, delivering revenue and earnings per share (EPS) that exceeded analyst expectations. However, the stoc... Full story

Yahoo Finance • 4 months ago

Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Strong Growth Stock with Breakout Potential

Neurocrine Biosciences Inc (NASDAQ:NBIX [https://www.chartmill.com/stock/quote/NBIX]) has been identified as a candidate through a screening strategy that finds strong growth stocks with favorable technical breakout patterns. This method b... Full story

Yahoo Finance • 4 months ago

Neurocrine Biosciences Grows Pipeline While Maintaining Steady Investor Confidence

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the 11 Best Long Term Low Risk Stocks to Invest in. Following the update on its ongoing clinical study, analysts are maintaining a Buy rating while raising the price target.Neurocrine B... Full story

Yahoo Finance • 5 months ago

Friday Insider Trading: Top Buys and Sells from Friday, July 13, 2025

This article summarizes the most significant insider buying and selling activities reported for US stocks on Friday, July 13, 2025. Top Insider Buys: Cumberland Pharmaceuticals Inc (NASDAQ:CPIX): Chairman and CEO A J Kazimi reported mult... Full story

Yahoo Finance • 5 months ago

Neurocrine reports positive results from Crenessity trial

[Neuron system disease] koto_feja/E+ via Getty Images * Neurocrine Biosciences (NASDAQ:NBIX [https://seekingalpha.com/symbol/NBIX]) reported one-year results from late-stage study of its experimental drug, Crenessity (crinecerfont), sho... Full story

Yahoo Finance • 5 months ago

Neurocrine Biosciences (NBIX) CSO Onyia sells $7.8m in stock

Neurocrine Biosciences Inc (NASDAQ:NBIX), a $13.2 billion biopharmaceutical company trading at $133.50 per share, reported a significant insider transaction. Chief Scientific Officer Jude Onyia sold 59,819 shares of common stock on July 9,... Full story

Yahoo Finance • 5 months ago

Crinetics Pharmaceuticals' SWOT analysis: stock poised for growth in endocrine treatments

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a $2.79 billion market cap biopharmaceutical company specializing in treatments for rare endocrine diseases and endocrine-related tumors, is positioning itself as a potential leader in the fie... Full story